See also:

CHAOS-2 study, 2002	TRC9988
	download pdf: folic acid | plasma homocysteine lowering intervention for cardiovascular prevention

Treatments

Studied treatment	folic acid 5 mg per day (for 2 years)
Control treatment	placebo

Patients

Patients	patient with CHD
Inclusion criteria	patients with with myocardial infarction or unstable angina or with Positive coronary angiogram

Method and design

Randomized effectives	942 / 940 (studied vs. control)
Design	Parallel groups
Blinding	double blind
Follow-up duration	1.7 y
Number of centre	multicenter
Primary endpoint	CV death, MI, revascularization

Results

Endpoint Studied treat.
n/N Control treat.
n/N Graph RR [95% CI]

Non fatal MI

23 / 942
12 / 940
classic 1,91 [0,96;3,82] 0 2 1.0

Relative risks
Endpoint	Events (%)		Relative Risk	95% CI	Endpoint definition in the trial	Ref
	Studied treat.	Control treat.
Non fatal MI	23 / 942 (2,4%)	12 / 940 (1,3%)	1,91	[0,96;3,82]		11305
The primary endpoint (if exists) appears in blod characters
Reference(s) used for data extraction: 11305: Mart�-Carvajal AJ, Sol� I, Lathyris D, Salanti GHomocysteine lowering interventions for preventing cardiovascular events.Cochrane Database Syst Rev 2009 Oct 7;:CD006612 0:

Endpoint	studied treat.	control treat.	mean diff

Absolute risk reduction (for a follow-up of 1.7 y)
Endpoint	Events rate		Absolute risk reduction (ARR)
	Studied treat.	Control treat.
Non fatal MI	2,44%	1,28%	1,2%

Meta-analysis of all similar trials:

plasma homocysteine lowering intervention in cardiovascular prevention for all type of patients

Reference(s)

TrialResults-center ID	TRC9988
Trials register #	NA

• Baker F, Picton D, Blackwood S, Hunt J, Erskine M, Dyas M, et al.. Baker F, Picton D, Blackwood S, Hunt J, Blinded comparison of folic acid and placebo in patients with ischaemic heart disease: an outcome trial [abstract]. Circulation 2002;106(Suppl II):741.
  Pubmed | Hubmed | Fulltext

(c) 2004-2015 TrialResults-center - All Rights Reserved